Spectros has entered into a patent sale agreement with Koninklijke Philips Electronics (PHG). Under the agreement, Philips purchased a patent related to technology for multispectral pulse oximetry, an approach developed and patented by Spectros.
Previously, Spectros has closed technology sale, license, or access agreements, including with LI-COR, Caliper Life Sciences, FirstScan, Merck Research, Rita Medical, and Boston Scientific.
Spectros claimed that its T-Stat VLS Tissue Oximeter is the first FDA-approved medical device as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the commercially-available tissue oximeter that utilizes white light-emitting diodes (LEDs) and broadband visible light spectroscopy (VLS) technology.
The non-invasive T-Stat system is used clinically to provide an absolute, continuous, and real-time tissue oxygenation value, utilizing 260 wavelengths versus only 2-4 wavelengths for competing NIRS products. The Spectros T-Stat competes in the ICU oximetry marketplace with noninvasive devices from Somanetics, CAS Medical, and Masimo and competes in the Plastic Surgery market with Vioptix.
David Benaron, CEO, said: “We are pleased that Philips has recognized the value inherent in Spectros’ intellectual property covering multispectral pulse oximetry. Spectros has one of the largest optical biotechnology portfolios in the medical, sensing, and illumination markets.”